Annovis Stock Insiders

ANVS -  USA Stock  

USD 13.04  0.49  3.62%

Annovis Bio employes about 2 people. The company is managed by 6 executives with total tenure of roughly 55 years, averaging almost 9.0 years of service per executive having 0.33 employees per reported executive. Discussion of Annovis Bio management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Annovis Bio future performance.
Please continue to Trending Equities.

Annovis Insiders 

 
Refresh
  Weixing Wang  Chairman
Chairman, CEO and Pres
  Tingyi Li  President
Vice President

Annovis Bio Management Team Effectiveness

Annovis Bio has return on total asset (ROA) of (23.06) % which means that it has lost $23.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (36.93) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/23/2022, Return on Average Assets is likely to drop to -0.69. In addition to that, Return on Average Equity is likely to drop to -0.55. Annovis Bio Total Assets are relatively stable at the moment as compared to the past year. Annovis Bio reported last year Total Assets of 9.34 Million. As of 01/23/2022, Current Assets is likely to grow to about 10.1 M, while Return on Average Assets are likely to drop (0.69) .

Annovis Bio Quarterly Total Assets

47.65 MillionShare
As of 01/23/2022, Weighted Average Shares is likely to grow to about 7.8 M. Also, Weighted Average Shares Diluted is likely to grow to about 7.8 M

Annovis Bio Workforce Comparison

Annovis Bio is rated second in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 15.0. Annovis Bio retains roughly 2.0 in number of employees claiming about 13% of stocks in Biotechnology industry.

Annovis Bio Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Annovis Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Annovis Bio Benchmark Summation

Operator
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was zero with a total number of output elements of sixty-one. Annovis Bio Price Series Subtraction is a subtraction of Annovis Bio price series from its benchmark/peer.. View also all equity analysis or get more info about price series subtraction math operators indicator.

Annovis Bio Notable Stakeholders

An Annovis Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Annovis Bio often face trade-offs trying to please all of them. Annovis Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Annovis Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Weixing Wang - Chairman, CEO and PresProfile
Tingyi Li - Vice PresidentProfile
Kevin Su - CFOProfile
Paul Strickland - Independent DirectorProfile
Yiquan Song - DirectorProfile
Humayun Shakeel - IR Contact OfficerProfile

About Annovis Bio Management Performance

The success or failure of an entity such as Annovis Bio often depends on how effective the management is. Annovis Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Annovis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Annovis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets(0.64) (0.69) 
Return on Average Equity(0.53) (0.55) 
Return on Invested Capital 26.30  21.09 
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 2 people.
The data published in Annovis Bio's official financial statements usually reflect Annovis Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Annovis Bio. For example, before you start analyzing numbers published by Annovis accountants, it's critical to develop an understanding of what Annovis Bio's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Annovis Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Annovis Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Annovis Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annovis Bio. Please utilize our Beneish M Score to check the likelihood of Annovis Bio's management to manipulate its earnings.

Annovis Bio Workforce Analysis

Traditionally, organizations such as Annovis Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Annovis Bio within its industry.

Annovis Bio Manpower Efficiency

Return on Annovis Bio Manpower

Revenue Per Employee183.3 K
Revenue Per Executive61.1 K
Net Loss Per Employee5.1 M
Net Loss Per Executive1.7 M
Working Capital Per Employee385 K
Working Capital Per Executive128.3 K
Please continue to Trending Equities. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.